NO129077B - - Google Patents
Download PDFInfo
- Publication number
- NO129077B NO129077B NO1526/69A NO152669A NO129077B NO 129077 B NO129077 B NO 129077B NO 1526/69 A NO1526/69 A NO 1526/69A NO 152669 A NO152669 A NO 152669A NO 129077 B NO129077 B NO 129077B
- Authority
- NO
- Norway
- Prior art keywords
- acid
- antacid
- suspension
- viscosity
- agent
- Prior art date
Links
- 230000001458 anti-acid effect Effects 0.000 claims description 125
- 239000003795 chemical substances by application Substances 0.000 claims description 83
- 238000002360 preparation method Methods 0.000 claims description 75
- 239000003159 antacid agent Substances 0.000 claims description 62
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 60
- 229940069428 antacid Drugs 0.000 claims description 58
- 229910019142 PO4 Inorganic materials 0.000 claims description 47
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 47
- 239000010452 phosphate Substances 0.000 claims description 47
- 239000000725 suspension Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 31
- 229910001868 water Inorganic materials 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 24
- 239000007900 aqueous suspension Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 11
- 239000000679 carrageenan Substances 0.000 claims description 10
- 229920001525 carrageenan Polymers 0.000 claims description 10
- 235000010418 carrageenan Nutrition 0.000 claims description 10
- 229940113118 carrageenan Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 5
- 239000000347 magnesium hydroxide Substances 0.000 claims description 5
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 2
- 239000000047 product Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 26
- 239000003826 tablet Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 239000004615 ingredient Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000002496 gastric effect Effects 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 14
- 210000003097 mucus Anatomy 0.000 description 13
- 229940079920 digestives acid preparations Drugs 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 239000006194 liquid suspension Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 210000005095 gastrointestinal system Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- -1 and if desired Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- RUJUQAPQALJUPC-UHFFFAOYSA-K bis[(2-aminoacetyl)oxy]alumanyl 2-aminoacetate Chemical compound [Al+3].NCC([O-])=O.NCC([O-])=O.NCC([O-])=O RUJUQAPQALJUPC-UHFFFAOYSA-K 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- PZAGQUOSOTUKEC-UHFFFAOYSA-N acetic acid;sulfuric acid Chemical compound CC(O)=O.OS(O)(=O)=O PZAGQUOSOTUKEC-UHFFFAOYSA-N 0.000 description 2
- LHPJBAIYHPWIOT-UHFFFAOYSA-K aluminum;magnesium;carbonate;hydroxide Chemical compound [OH-].[Mg+2].[Al+3].[O-]C([O-])=O LHPJBAIYHPWIOT-UHFFFAOYSA-K 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940049676 bismuth hydroxide Drugs 0.000 description 2
- TZSXPYWRDWEXHG-UHFFFAOYSA-K bismuth;trihydroxide Chemical compound [OH-].[OH-].[OH-].[Bi+3] TZSXPYWRDWEXHG-UHFFFAOYSA-K 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229940099273 magnesium trisilicate Drugs 0.000 description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 description 2
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JPKKQJKQTPNWTR-KQAYXBCTSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 JPKKQJKQTPNWTR-KQAYXBCTSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- UWFFNDSXSPUNTR-UHFFFAOYSA-N aluminum magnesium silicic acid trihydroxy(oxido)silane silicate Chemical compound [Mg+2].[Al+3].O[Si](O)(O)O.O[Si](O)(O)[O-].[O-][Si]([O-])([O-])[O-] UWFFNDSXSPUNTR-UHFFFAOYSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011425 standardization method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72217668A | 1968-04-18 | 1968-04-18 | |
| US78572768A | 1968-12-20 | 1968-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO129077B true NO129077B (fr) | 1974-02-25 |
Family
ID=27110553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1526/69A NO129077B (fr) | 1968-04-18 | 1969-04-15 |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS4621672B1 (fr) |
| AU (1) | AU438147B2 (fr) |
| BE (1) | BE731695A (fr) |
| CA (1) | CA959760A (fr) |
| CH (1) | CH536114A (fr) |
| DE (1) | DE1919802A1 (fr) |
| DK (1) | DK127269B (fr) |
| ES (1) | ES366173A1 (fr) |
| FI (1) | FI50831C (fr) |
| FR (1) | FR2007475A1 (fr) |
| GB (1) | GB1269987A (fr) |
| IL (1) | IL32020A (fr) |
| NL (1) | NL6906087A (fr) |
| NO (1) | NO129077B (fr) |
| SE (1) | SE388356B (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK154265B (da) * | 1979-07-09 | 1988-10-31 | Haessle Ab | Fremgangsmaade til stabilisering af en vandig mavesyreneutraliserende suspension |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1401257A (en) * | 1972-06-30 | 1975-07-16 | Miles Lab | Process for preparing a spray dried calcium carbonate composition |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| SG72632A1 (en) * | 1985-04-18 | 2000-05-23 | Procter & Gamble | Treatment of non-ulcer dyspepsia with bismuth salts |
| IT1215332B (it) * | 1987-01-12 | 1990-02-08 | Crinos Industria Farmaco | Composizione farmaceutica contenente sulglicotide per la terapia dell'ulcera gastrica |
| DE3812378A1 (de) * | 1988-04-14 | 1989-10-26 | Theo Mertens | Mobile erntegutmahl- und -mischvorrichtung |
| US4988679A (en) * | 1989-01-03 | 1991-01-29 | Leonard Chavkin | Liquid sustained release composition |
| US4980175A (en) * | 1989-01-03 | 1990-12-25 | Leonard Chavkin | Liquid orally administrable compositions based on edible oils |
| DE4305919A1 (de) * | 1993-02-26 | 1994-09-01 | Ruediger Potthoff | Transportsilo für Kunststoff-Granulat |
| WO2003066022A2 (fr) * | 2002-02-04 | 2003-08-14 | Pharmacia Corporation | Preparation pharmaceutique stable pour le traitement des troubles gastro-intestinaux |
| AU2003211627A1 (en) * | 2002-03-04 | 2003-09-16 | Medrx Co., Ltd. | Liquid matrix undergoing phase transfer in vivo and liquid oral preparations |
| US20030232092A1 (en) * | 2002-06-14 | 2003-12-18 | Hasenmayer Donald L. | Liquid antacid compositions |
| AU2015253187B2 (en) | 2014-04-29 | 2017-10-05 | The Procter & Gamble Company | Method for making bismuth-containing liquid pharmaceutical suspensions |
| US9486460B2 (en) | 2014-04-29 | 2016-11-08 | The Procter & Gamble Company | Bismuth containing liquid pharmaceutical suspensions |
| CN114732828A (zh) * | 2022-04-27 | 2022-07-12 | 广西南宁百会药业集团有限公司 | 一种铝碳酸镁混悬液及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE621147A (fr) * |
-
1969
- 1969-04-14 IL IL32020A patent/IL32020A/en unknown
- 1969-04-14 GB GB09070/69A patent/GB1269987A/en not_active Expired
- 1969-04-15 NO NO1526/69A patent/NO129077B/no unknown
- 1969-04-15 FI FI691089A patent/FI50831C/fi active
- 1969-04-16 AU AU53539/69A patent/AU438147B2/en not_active Expired
- 1969-04-16 CA CA048,813A patent/CA959760A/en not_active Expired
- 1969-04-17 DK DK209369AA patent/DK127269B/da unknown
- 1969-04-17 ES ES366173A patent/ES366173A1/es not_active Expired
- 1969-04-18 CH CH593269A patent/CH536114A/fr not_active IP Right Cessation
- 1969-04-18 SE SE6905549A patent/SE388356B/xx unknown
- 1969-04-18 DE DE19691919802 patent/DE1919802A1/de not_active Ceased
- 1969-04-18 BE BE731695D patent/BE731695A/xx unknown
- 1969-04-18 NL NL6906087A patent/NL6906087A/xx unknown
- 1969-04-18 FR FR6912182A patent/FR2007475A1/fr not_active Withdrawn
- 1969-04-18 JP JP3015469A patent/JPS4621672B1/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK154265B (da) * | 1979-07-09 | 1988-10-31 | Haessle Ab | Fremgangsmaade til stabilisering af en vandig mavesyreneutraliserende suspension |
Also Published As
| Publication number | Publication date |
|---|---|
| SE388356B (sv) | 1976-10-04 |
| AU438147B2 (en) | 1973-07-18 |
| ES366173A1 (es) | 1971-04-01 |
| DK127269B (da) | 1973-10-15 |
| CA959760A (en) | 1974-12-24 |
| IL32020A0 (en) | 1969-06-25 |
| BE731695A (fr) | 1969-10-20 |
| NL6906087A (fr) | 1969-10-21 |
| GB1269987A (en) | 1972-04-12 |
| FR2007475A1 (fr) | 1970-01-09 |
| JPS4621672B1 (fr) | 1971-06-19 |
| FI50831B (fr) | 1976-04-30 |
| IL32020A (en) | 1972-11-28 |
| FI50831C (fi) | 1976-08-10 |
| DE1919802A1 (de) | 1969-11-06 |
| CH536114A (fr) | 1973-04-30 |
| AU5353969A (en) | 1970-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO129077B (fr) | ||
| US5167965A (en) | Palatable cholestyramine granules, tablets and methods for preparation thereof | |
| EP0278464A1 (fr) | Composition de cholestyramine et procédé pour la préparer | |
| JPH0535130B2 (fr) | ||
| US4181718A (en) | Polyanion-stabilized aluminum hydrogels | |
| US3579634A (en) | Novel antacid compositions and methods for their administration | |
| JPH06500576A (ja) | 制御解放ベラパミルタブレット | |
| EP3184115B1 (fr) | Composition orale pour le traitement du reflux gastro- sophagien | |
| US4704278A (en) | Fluidized magaldrate suspension | |
| US3272704A (en) | Stable aluminum hydroxide-magnesium compound codried gel antacids and process of making the same | |
| JPS61501916A (ja) | 制酸組成物 | |
| JP2735559B2 (ja) | 懸濁液 | |
| US4465667A (en) | Process for the preparation of gastric acid neutralizing agents, gastric acid neutralizing agents, and a method for treating hyperacidity and disorders related thereto | |
| EP0452416A1 (fr) | Compositions liquides a base d'huiles comestibles pour administration par voie orale. | |
| US3326755A (en) | Alginate containing antacid compositions | |
| KR100293045B1 (ko) | 팽창성설사제로서의무가당무수혼합셀룰로스에테르조성물 | |
| EP2806880A1 (fr) | Composition pharmaceutique comme substance pour un médicament antiacide antireflux | |
| DK167737B1 (da) | Vandig eller rehydratiserbar, antacid sammensaetning og fremgangsmaade til dens fremstilling | |
| US2935447A (en) | Appetite depressant containing alginate | |
| US5661137A (en) | Antacid pharmaceutical composition in the form of a suspension based on sucralfate gel | |
| CA1252045A (fr) | Suspension fluidisee de magaldrate | |
| US3208906A (en) | Glycine-stabilized aluminum hydroxidemagnesium compound codried gel antacids and process of making the same | |
| US2461702A (en) | Composition for fluoroscopic observation and roentgenography | |
| NZ198858A (en) | Pharmaceutical composition containing sodium cromoglycate | |
| WO1986006632A1 (fr) | Compositions antiacides a action prolongee |